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Background: Subarachnoid hemorrhage is a common and dangerous disease with an unfavorable prognosis.
Patients with poor-grade subarachnoid hemorrhage (Hunt & Hess Grades 4–5) are unconscious on admission.
Because of the high mortality and disability rate associated with poor-grade subarachnoid hemorrhage, it is often
treated conservatively. Timing of surgery for poor-grade aneurysmal subarachnoid hemorrhage is still controversial,
therefore this study aims to identify the optimal time to operate on patients admitted in poor clinical condition.
Methods/design: Ninety-nine patients meeting the inclusion criteria were randomly assigned into three treatment
groups. The early surgery group received operation within 3 days after onset of subarachnoid hemorrhage (day of
SAH = day 1); the intermediate surgery group received operation from days 4 to 7, and surgery was performed on
the late surgery group after day 7. Follow-up was performed 1, 3, and 6 months after aneurysm clipping. Primary
indicators of outcome included the Extended Glasgow Outcome Scale and the Modified Rankin Scale, while
secondary indicators of outcome were assessed using the Barthel Index and mortality.
Discussion: This is the first prospective, single-center, observer-blinded, randomized controlled trial to elucidate optimal
timing for surgery in poor-grade subarachnoid hemorrhage patients. The results of this study will be used to direct
decisions of surgical intervention in poor-grade subarachnoid hemorrhage, thus improving clinical outcomes for patients.
Trial registration: Chinese Clinical Trial Registry: ChiCTR-TRC-12002917
Keywords: Timing of surgery, Poor-grade, Subarachnoid hemorrhage, ICP, PrognosisBackground
Subarachnoid hemorrhage (SAH) is a common fetal cere-
brovascular disease. Its annual incidence is 2–32 cases
per 100,000 population, and contributes to 5% of stroke
cases [1,2]. More than 85% of SAH are caused by aneu-
rysms [3]. Poor grade aneurysmal subarachnoid hemorrhage
(PGASAH) , is classified as Grade IV and V and accounts
for approximately 20-40% of patients with SAH [4]. The
prognosis of PGASAH is extraordinarily poor. More
than 60% patients will become dependent or will die [5,6].
Without surgical intervention, the mortality rate of
PGASAH can reach more than 90% [7].
Neurosurgical clipping and endovascular coiling are con-
sidered two main treatments for patients with intracranial* Correspondence: doctorcastor@gmail.com
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reproduction in any medium, provided the oraneurysm. Whether patients with aneurysms can benefit
from surgery is still controversial, especially for those
with PGASAH, which is the most critical subtype of SAH.
In 2003, Maurice-Williams RS asserted the history of
aneurysm surgery would end with experienced neurosur-
geons is draining away as a result of death and retirement
[8]. However, the truth of the matter was quite different.
Previous trials have been performed to compare the prog-
nosis of neurosurgical clipping and endovascular coiling.
The most significant study is the International Subarach-
noid Aneurysm Trial (ISAT) conducted by Molyneux et al.
[9]. Two thousand one hundred forty three patients with
aSAH were randomly divided into neurosurgical clipping
(n = 1070) or endovascular treatment. Outcomes at 1 year
indicated that although the rebleeding rate was more com-
mon after endovascular coiling than neurosurgical clipping,
endovascular coiling resulted in better clinical outcomes.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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timal timing of surgery may not have been considered, be-
cause a 14 hours lapse in the intervention timing of the two
treatments. Second, the study excluded more cases that
were suitable for neurosurgical clipping. Third, the study
didn’t include middle cerebral aneurysms. Fourth, long-
term follow-up outcomes were unknown. Fifth, The ISAT
study ignored a selection bias, with major surgical interven-
tion centers in the United States and Japan being excluded
[10]. Furthermore, the ISAT Collaborative Group distinctly
known that the number of patients younger than 40 years
or older than 70 years was small, no consistent trend for
age was observed. And a limited number of patients with
PGASAH were enrolled in the ISAT study [9]. So, the con-
clusion that patients with aSAH who received endovascular
coiling showed a better clinical outcome than those re-
ceived neurosurgical clipping should be suspected.
The timing of surgical intervention for SAH has
been debated worldwide. Pros and cons exist for patients
with PGASAH who received different timing of surgery.
PGASAH patients are more prone to encounter rebleeding
than patients in good clinical condition [11-14]. Early sur-
gery can secure the aneurysm neck to avoid rebleeding
which would cause irreparable outcomes, and reduce dis-
ability rate and mortality [6]. If the patient receives early
surgery, triple-H therapy can be performed as soon as
possible to avoid vasospasm postoperatively [14,15]. How-
ever, in early surgery, serious cerebral edema may cause
brain injury, postoperative hemorrhage, difficult exposure
of the aneurysm intraoperatively and other operative com-
plications [16]. The advantages of delayed surgery include
the less brain swelling and less cerebrovascular instability
during the surgery. Decline in operative mortality have
been associated with the operation that is relatively easy.
However, the aneurysm may rupture again if surgery is
delayed, thus increasing mortality [17].
Surgery timing for patients with PGASAH have the
most uncertainty. Previous authors [5,18-21] carried out
many researches on the surgery timing of PGASAH, yet
a surgery timing still remains unclear. However, till now,
only one prospective randomized study has been detected.
Ohman et al. randomized 216 patients with SAH in clin-
ical Grades I to III (according to the Hunt & Hess classifi-
cation) into three operation groups: acute surgery (0 to
3 days after SAH), intermediate surgery (4 to 7 days after
SAH), or late surgery (after day 7). At 3 months post-SAH,
clinical outcomes indicated that there was no differ-
ence in the prognosis of the three groups [18]. In 2002,
Ross et al. reported a study enrolled 1168 patients with
SAH, and the outcomes indicated that there were no
significant difference at discharge or 6 months between
the early group (day 1–3), intermediate group (day 4–10)
and late group (day 11–21). However, this study was
only concerned with the prognosis of surgical patients,ignored the relationship between clinical grades, rebleeding
and prognosis [19], the outcomes were widely suspected.
Hutchinson et al. [5] reported their study with comparable
outcomes, and their study contained similar shortfalls in
analysis (as mentioned above). In 2002, de Gans et al.
performed a systematic review, where only 11 studies, 1
randomized clinical trial and 10 observational studies,
met the inclusion criteria [20]. Meta-analysis showed
that outcomes were better after early or intermediate
surgery than after late surgery, for patients who were in
good clinical condition at admission. For patients in poor
clinical condition, results suggest only a trend toward a
better outcome for early or intermediate surgery when
compared with late surgery. In 2005, Nieuwkamp et al.
reported an observational study, which included 411 pa-
tients. The study demonstrated that clinical prognosis
of patients in poor clinical condition on admission who
received early surgery was statistically better than late
surgery [21]. It is easy to detect that there is no random-
ized controlled trial concern about PGASAH.
The controversy over the optimum timing of surgery for
patients with PGASAH has continued for many years, and
evidence for the optimal timing of surgery in this condition
is still insufficient. No randomized controlled trial specific-
ally concerning PGASAH has currently been performed.
We designed a trial to evaluate the prognosis of patients
with PGASAH receiving surgery at different times, with the
aim to identify optimal timing for surgical intervention.
Methods/design
Study objective
To compare the efficacy of different timing for surgical
intervention in PGASAH. We will also attempt to screen
patients with PGASAH who would benefit from surgical
intervention.
Overview of study design
West China hospital receives the most patients with
PGASAH in western of China. This study is a prospective,
single-centre, observer-blinded, randomized controlled
trial with stratification according to the patient’s age,
gender, Hunt & Hess grading and the size of aneurysm.
Ninety-nine patients meeting the criteria will be ran-
domly assigned into three treatment groups. The early
surgery group will receive operation within 3 days after
onset of SAH, the intermediate surgery group from days
4 to 7, and the late surgery group after day 7 post-SAH.
Sample size
The rate of unfavorable outcomes in patients with PGASAH
is approximately 50% [22]. A statistically significant dif-
ference in unfavorable outcomes between the different
surgery times is 30%, which would have statistically sig-
nificant differences. A sample size of 88 will be required
Zhang et al. BMC Neurology 2013, 13:108 Page 3 of 6
http://www.biomedcentral.com/1471-2377/13/108with 80% power and a 5% (2-sided) significance level.
On consideration of the loss to follow-up, the sample
size will be increased to 99 subjects.
Inclusion criteria
 Age between 18 to 80 years old.
 Patient diagnosed with a definite subarachnoid
hemorrhage, using computed tomography (CT) or
lumbar puncture.
 Patient had at least one intracranial aneurysm,
detected by DSA, MRA or CT angiography, which was
responsible for the recent subarachnoid hemorrhage.
 Patient was in poor neurological condition (Hunt &
Hess Grades IV or V) on admission.
 No more than 72 hours from onset to admission.
 According to ethics committee requirements, the
person responsible for the patient must agree to









 Pregnant or lactating women.
 The person responsible for the patient refused to
give consent to participate in this trial.
 Patient was participating in another randomized
clinical trial for treatment of SAH.
Withdrawal from the study
 Even if patients are included in the trial, the
person responsible for the patient can withdraw
informed consent at any time.
 If severe adverse events occur, patients can be
withdrawn from the study on consideration of their
personal safety.
 If the person responsible for the patient decides to
abandon treatment, patient will be withdrawn as
they do not fully participate in the trial.
Randomization
Minimization, a kind of balance randomization method,
will be used in this trial. Characteristics of patients who
meet the selection criteria will be submitted to random
analyst. After the data is entered into a computer, patientswill be randomly divided into an early, intermediate
or late surgery group using specialized minimization
software. Once random allocation has been determined,
groups cannot be changed. Stratified randomization will
be employed. Four stratification factors will be applied to
achieve balanced randomization: 1) patient’s age, 2) gender,
3) Hunt & Hess grading and 4) the size of aneurysm.
Blinding
Because of the nature of the study, only the observer can
be blinded. In order to prevent bias, the following mea-
sures will be taken. 1) Patient characteristics will be
collected and evaluated by two special doctors who are
not involved in any other stage of the trial. 2) Patient
randomization will be performed by an independent
random analyst. 3) Patient outcomes will be followed
up by two special investigators who are not involved in
the allocation or the treatment process. 4) Statistical
analysis will be performed by a special statistician who
did not participate in the implementation of the study.
5) Because of the sequence of the Case Report Form
(CRF), each stage of the study will be completed in a
specific order by the allocated individuals. Patient char-
acteristics will be the first section completed, followed
by the independent random analyst, subsequently the
neurosurgeons will describe the treatment procedure,
complications, adverse and severe adverse events in the
CRF, the last will be the two special investigators. All
the researchers will submit a copy of their original data
to the Quality Monitoring Board (QMB), before the CRF
is available.
Treatment
All patients with SAH admitted in poor neurological
condition (Hunt & Hess IV–V) will receive effective treat-
ment, according to guidelines for the management of
aSAH that published in 2012[24]. Aggressive resuscita-
tion, including intubation, ventilation, and mannitol
administration, will be implemented in the emergency
department. CT scan will be performed as soon as
possible after admission. Intracranial pressure (ICP)-
monitoring sensor implantation (Codman Group Inc)
will be performed on all identified patients after admission
to continuously measure ICP. If aSAH-related hydroceph-
alus is confirmed by CT scan, both external ventricular
drain (EVD) and ICP-monitoring sensor implantation will
be performed. ICP-targeted treatment will be given to
patients with elevated ICP. These therapeutic measures
include head elevation to 30°, hyperosmolar therapy,
tracheal intubation, sedation and analgesia, and mild
hypothermia. Neurosurgical clipping will be performed
at different times, according to the randomized grouping.
Aneurysms of the anterior circulation were approached
through the standard pterional craniotomy and all
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tively, patients will return to the neurosurgical intensive
care unit (NICU) for intensive monitoring.Follow-up
Two investigators (senior neurosurgeons) that are not
involved in allocation or treatment will follow up of all
patients at 1, 3, and 6 months after neurosurgical clip-
ping. Primary outcomes of the trial are the Extended
Glasgow Outcome Scale and the Modified Rankin Scale
(mRS) at 6 months after aneurysm clipping. Both scales
will be measured with structured interviews. The second-
ary indicators include the Barthel Index and mortality.Data collection and handling
All relevant information will be collected using a case
report form (CRF). Double data input will be used for
the data entry, and will be checked at the second input.
The QMB and the principal investigator will check and
examine the data, which will then be secured and sent
to the statistician.Ethical issues
The final study protocol and the final of written in-
formed consent form were approved by the Biological
and Medical Ethics Committee (BMEC) of West China
Hospital (2012 Reviewed-No.114). Good Clinical Prac-
tice and ethical principles described in the Declaration
of Helsinki will be strictly adhered to guarantee patient
rights. The trial will be carried out in keeping with local
laws and regulations. Full disclosure will be given to the
person responsible for the patient. The information will
be given before the person responsible agrees to partici-
pate in this trial and signs the informed consent, and
will include the natural history of SAH, the treatment
procedure, risks, possible consequences and the costs of
PGASAH. Patients can be withdrawn from the trial for
any reason and at any time.Adverse and severe adverse events
Adverse events (AE) are defined as any unwanted inci-
dents in patients during the trial. Coma was excluded as
an AE, because all patients enrolled in the trial were in
poor neurological condition on admission. Serious adverse
events (SAE) are defined as death or vegetative state. Both
AEs and SAEs will be recorded on the CRF, including
the details of the event, the correlation with the trial,
the start and the end date, treatments used, their effi-
cacy and outcomes. In the case of AEs and SAEs, the
BMEC and QMB will be informed within 24 hours after
the SAEs are detected .Statistical analysis
Intention-to-treat (ITT) analysis and per-protocol (PP)
analysis will be performed. The level of significance re-
quired for 80% power and a 5% (2-sided) significance
level will be used. All data will be analyzed by the statis-
tical analysis using Statistical Package for Social Sciences
software (SPSS), version 17.0. Quantitative variables will
be analyzed using t-test. Chi-square test and Fisher’s
exact test will be used to analyze categorical variables.
To analyze the outcome at 6 months after surgery, a
comparison between groups will be made using the
Mann–Whitney U-test and the significance of observed
differences in outcome will be assessed with the Fisher’s
exact test. Survival analysis will be further compare mor-
tality between groups. Logistic regression will be used to
adjust the effect of multivariable.
Discussion
Many neurosurgeons are reluctant to treat patients with
PGASAH, because the disease burden higher mortality,
higher disability, more medical care costs, and higher med-
ical risks. Although neurosurgery has rapidly developed
in recent years, the prognosis of PGASAH remains dis-
mal. Controversy surrounding the optimal timing of surgery
for PGASAH still continues. In spite of many difficul-
ties, we carried out the trial on the consideration of the
following reasons: First, although many neurosurgeons
have done much work on the timing of surgery for
PGASAH, there is a lack of randomized controlled trial
focusing specifically on this condition. Second, no opti-
mal timing, no better surgical intervention outcome.
The prognosis for PGASAH is poor, owing to the nature
of the disease, but also contributed to the timing of
surgery. Third, there has been great progress both in
neurosurgical clipping and endovascular coiling. The
comparability of treatment outcome between neurosurgi-
cal clipping and endovascular coiling should be suspected,
if the outcome of PGASAH that yield by the optimal sur-
gical timing is lacking. In a similar way,the lack of optimal
timing for coiling [25] may prevent the clinical outcomes
of these two treatments from being comparable.
As we know, the prognosis of PGASAH is affected by
many factors. The timing of surgery for PGASAH plays
an important role in patient outcomes. The factors that
cause the initial poor condition of patients with PGASAH
are still not clear. Few studies have focused on ICP of the
PGASAH. What is the range of ICP in PGASAH? And
whether there is a relationship between the elevated intra-
cranial pressure (EICP) and the PGASAH? The peak value
of ICP that patients with PGASAH can withstand, the
duration of this EICP and the ideal ICP in optimal timing
for surgery are all variables we wish to elucidate from our
study. The study considerations of our trial are presented
in Figure 1.
The peak value of 
ICP to patients with 
PGASAH
The range of ICP 
of the PGASAH
The range of ICP when 
operation is performed 
on the optimal timing
ICP in PGASAH
Timing of operation 
for PGASAH
The prognosis of 
PGASAH
Figure 1 The study considerations of our trial.
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forms of bias and improve accuracy. The experience of
presciously authors was noted and was merged into our
design of the trial [19-21]. We will record all treatment
results and surgical results, but only treatment results
will be utilized for analysis. This will avoid selection
bias, because all treatment results will include patients
that may die from rebleeding, vasospasm or other com-
plications, when awaiting surgery, especially those pa-
tients assigned to the intermediate or late surgery groups.
Patients in intermediate or late surgery groups will receive
emergency surgery when space-occupying hematoma,
midline shift and emergency surgery indications are con-
firmed. Bias will be solved through the use of ITT analysis.
Although previous reports have demonstrated that
patients in poor condition on admission within 6 hours
after the onset of SAH achieved better outcomes than
patients admitted later [12,26], this trial will enroll all
the patients with PGASAH on admitted within 72 hours.
As one of the largest hospitals in China, the number of
patients admitted within 6 hours after the onset of SAH
was relatively small in our department. More patients
are transferred from other cities, even from the outlying
areas in the west of China, and which takes time. The
trial was not designed to include a small number ofpatients, but to include the overwhelming majority of
the patients.
Neurosurgeon experience is an important factor in
outcome after SAH. More than 4,000 surgeries are com-
pleted in our Department of Neurosurgery every year.
Every neurosurgeon participating in the trial has accu-
mulates experience of more than 200 neurosurgical clip-
pings yearly, thus ensuring that every surgery will be
performd to a high standard.
According to previous report, the major risk of rebleeding
after SAH presented within the first 6 to 12 hours, and
the risk of ultra-early rebleeding was even higher for pa-
tients with PGASAH [10]. Many neurosurgeons attempted
to performed early or ultra-early/urgent surgery on
the patients with PGASAH [21,27], so that prevented
rebleeding. However, some authors detected the inci-
dence of rebleeding with a higher frequency [28,29], even
as high as 89% [30], during emergency cerebral angiog-
raphy within 6 hours after initial SAH. As we know, the
frequence of rebleeding will increase during cerebral angi-
ography, because the thrombus at the aneurysm dome is
still fragile only a few hours after initial SAH, and the
injection of contrast medium may suddenly increase
the intra-arterial pressure. Indeed, ultra-early surgery
did not improve the rebleeing rates and clinical outcomes
of patients [31,32]. Therefore, whether the patients with
PGASAH benefit from early or ultra-early/urgent surgery
is still unclear.
In conclusion, evidence for the optimum timing of sur-
gery is still insufficient. We will evaluate the prognosis
of patients with PGASAH receiving surgery at different
times, aiming to identify optimum timing for interven-
tion in these cases.
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